Stoke Therapeutics (STOK) Non-Current Deffered Revenue (2022 - 2026)

Stoke Therapeutics' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 35.61% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (down 35.61% YoY), while the FY2025 annual figure was $7.0 million, changed N/A from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $6.6 million, down from $7.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $49.5 million in Q1 2022, with the low at $6.6 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $29.1 million (2023), against an average of $26.0 million.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue sank 79.64% in 2024, then increased 3.22% in 2025.
• Stoke Therapeutics' Non-Current Deffered Revenue stood at $36.9 million in 2022, then decreased by 10.26% to $33.1 million in 2023, then plunged by 74.93% to $8.3 million in 2024, then decreased by 16.04% to $7.0 million in 2025, then retreated by 5.14% to $6.6 million in 2026.
• Business Quant data shows STOK's Non-Current Deffered Revenue at $6.6 million in Q1 2026, $7.0 million in Q4 2025, and $8.6 million in Q3 2025.